Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Somnomed Limited ( (AU:SOM) ) has issued an update.
SomnoMed Limited announced that its FY25 Financial Results and Investor Presentation will be released to the ASX on August 28, 2025. Co-CEOs Karen Borg and Amrita Blickstead, along with CFO Ye-Fei Guo, will host a webinar to discuss the results and engage in a Q&A session with investors. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited is a public company specializing in treatment solutions for sleep-related breathing disorders such as obstructive sleep apnea, snoring, and bruxism. The company is known for its clinically proven medical oral appliance therapy, SomnoDent®, which has been used by over 1 million patients in more than 20 countries.
Average Trading Volume: 68,622
Technical Sentiment Signal: Hold
Current Market Cap: A$167.5M
Learn more about SOM stock on TipRanks’ Stock Analysis page.